These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21606599)

  • 1. The targeted podocyte.
    Fogo AB
    J Clin Invest; 2011 Jun; 121(6):2142-5. PubMed ID: 21606599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.
    Gödel M; Hartleben B; Herbach N; Liu S; Zschiedrich S; Lu S; Debreczeni-Mór A; Lindenmeyer MT; Rastaldi MP; Hartleben G; Wiech T; Fornoni A; Nelson RG; Kretzler M; Wanke R; Pavenstädt H; Kerjaschki D; Cohen CD; Hall MN; Rüegg MA; Inoki K; Walz G; Huber TB
    J Clin Invest; 2011 Jun; 121(6):2197-209. PubMed ID: 21606591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.
    Inoki K; Mori H; Wang J; Suzuki T; Hong S; Yoshida S; Blattner SM; Ikenoue T; Rüegg MA; Hall MN; Kwiatkowski DJ; Rastaldi MP; Huber TB; Kretzler M; Holzman LB; Wiggins RC; Guan KL
    J Clin Invest; 2011 Jun; 121(6):2181-96. PubMed ID: 21606597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR in podocyte function: is rapamycin good for diabetic nephropathy?
    Lu MK; Gong XG; Guan KL
    Cell Cycle; 2011 Oct; 10(20):3415-6. PubMed ID: 22067710
    [No Abstract]   [Full Text] [Related]  

  • 5. Translationally controlled tumour protein is associated with podocyte hypertrophy in a mouse model of type 1 diabetes.
    Kim DK; Nam BY; Li JJ; Park JT; Lee SH; Kim DH; Kim JY; Kang HY; Han SH; Yoo TH; Han DS; Kang SW
    Diabetologia; 2012 Apr; 55(4):1205-17. PubMed ID: 22311416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of high mobility group box 1 (HMGB1) attenuates podocyte apoptosis and epithelial-mesenchymal transition by regulating autophagy flux.
    Jin J; Gong J; Zhao L; Zhang H; He Q; Jiang X
    J Diabetes; 2019 Oct; 11(10):826-836. PubMed ID: 30864227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Ragulator in the Regulation of Mechanistic Target of Rapamycin Signaling in Podocytes and Glomerular Function.
    Yao Y; Wang J; Yoshida S; Nada S; Okada M; Inoki K
    J Am Soc Nephrol; 2016 Dec; 27(12):3653-3665. PubMed ID: 27032892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
    Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
    Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TXNIP deficiency mitigates podocyte apoptosis via restraining the activation of mTOR or p38 MAPK signaling in diabetic nephropathy.
    Song S; Qiu D; Wang Y; Wei J; Wu H; Wu M; Wang S; Zhou X; Shi Y; Duan H
    Exp Cell Res; 2020 Mar; 388(2):111862. PubMed ID: 31982382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.
    Huber TB; Walz G; Kuehn EW
    Kidney Int; 2011 Mar; 79(5):502-11. PubMed ID: 21085109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.
    Eid S; Boutary S; Braych K; Sabra R; Massaad C; Hamdy A; Rashid A; Moodad S; Block K; Gorin Y; Abboud HE; Eid AA
    Antioxid Redox Signal; 2016 Nov; 25(13):703-719. PubMed ID: 27393154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paecilomyces cicadae-fermented Radix astragali activates podocyte autophagy by attenuating PI3K/AKT/mTOR pathways to protect against diabetic nephropathy in mice.
    Yang F; Qu Q; Zhao C; Liu X; Yang P; Li Z; Han L; Shi X
    Biomed Pharmacother; 2020 Sep; 129():110479. PubMed ID: 32768963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells.
    Yao Y; Inoki K
    Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):28-34. PubMed ID: 26625863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end-products suppress autophagic flux in podocytes by activating mammalian target of rapamycin and inhibiting nuclear translocation of transcription factor EB.
    Zhao X; Chen Y; Tan X; Zhang L; Zhang H; Li Z; Liu S; Li R; Lin T; Liao R; Zhang Q; Dong W; Shi W; Liang X
    J Pathol; 2018 Jun; 245(2):235-248. PubMed ID: 29570219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans.
    Puelles VG; van der Wolde JW; Wanner N; Scheppach MW; Cullen-McEwen LA; Bork T; Lindenmeyer MT; Gernhold L; Wong MN; Braun F; Cohen CD; Kett MM; Kuppe C; Kramann R; Saritas T; van Roeyen CR; Moeller MJ; Tribolet L; Rebello R; Sun YB; Li J; Müller-Newen G; Hughson MD; Hoy WE; Person F; Wiech T; Ricardo SD; Kerr PG; Denton KM; Furic L; Huber TB; Nikolic-Paterson DJ; Bertram JF
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31534053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin-Resistant mTOR Activity Is Required for Sensory Axon Regeneration Induced by a Conditioning Lesion.
    Chen W; Lu N; Ding Y; Wang Y; Chan LT; Wang X; Gao X; Jiang S; Liu K
    eNeuro; 2016; 3(6):. PubMed ID: 28101526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin signaling in the podocyte.
    Inoki K; Huber TB
    Curr Opin Nephrol Hypertens; 2012 May; 21(3):251-7. PubMed ID: 22388550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTOR regulates autophagic flux in the glomerulus.
    Cinà DP; Onay T; Paltoo A; Li C; Maezawa Y; De Arteaga J; Jurisicova A; Quaggin SE
    Autophagy; 2012 Apr; 8(4):696-8. PubMed ID: 22441016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
    Fan QW; Weiss WA
    Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.